NASDAQ : RGC
Regencell Bioscience Holdings Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Hong Kong
Last price 6.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.33B |
| Enterprise Value | 3.31B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 495.88M |
| Shares Outstanding | 495.88M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 88.55% |
| Owned by Institutions (%) | 0.35% |
| Float | 55.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 249.26 |
| P/TBV Ratio | 249.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.77 |
| Quick Ratio | 10.75 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -128.52% |
| Return on Assets (ROA) | -71.54% |
| Return on Invested Capital (ROIC) | -76.93% |
| Return on Capital Employed (ROCE) | -87.44% |
| Weighted Average Cost of Capital (WACC) | 10.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -59.60% |
| 50-Day Moving Average | 6.83 |
| 200-Day Moving Average | 17.15 |
| Relative Strength Index (RSI) | 42.78 |
| Average Volume (20 Days) | 423,761 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 440,717 |
| Short Previous Month | 656,182 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 1.71 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.72M |
| Pretax Income | -11.70M |
| Net Income | -11.70M |
| EBITDA | -11.64M |
| EBIT | -11.72M |
| Earnings Per Share (EPS) | -$0.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 14.19M |
| Total Debt | 295,811 |
| Net Cash | 13.90M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | 13.35M |
| Book Value Per Share | 0.03 |
| Working Capital | 12.90M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.70M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 80,908 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.70M |
| FCF Per Share | -$0.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | -0.35% |
| FCF Yield | -0.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 16, 2025 |
| Split Type | Forward |
| Split Ratio | 38:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |